T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects DOI Creative Commons
Irene Segato, Dalila Mele, Greta Forlani

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1451 - 1451

Опубликована: Дек. 23, 2024

Background/Objectives: New SARS-CoV-2 variants are continuously emerging, making it essential to assess the efficacy of vaccine-induced immune protection. Limited information is available regarding T cell responses BA.2.86 and JN.1 variants, particularly in elderly individuals. Methods: We evaluated total IgG against receptor-binding domain (RBD) ancestral strain, as well omicron subvariants, two groups subjects. One group consisted SARS-CoV-2-exposed individuals who were fully vaccinated with BNT162B2 mRNA vaccine, a booster dose updated 2023–2024 COVID-19 vaccine (XBB.1.5) at least 15 days after receiving vaccine. The second healthcare workers unexposed one month first-generation BNT162b2 activation-induced markers (AIM) IFN-γ secretion by flow cytometry ELISpot assays, respectively. Results: Elderly subjects showed reduced levels compared strain. stimulation resulted lower versus COVID-19-naïve group. AIM analysis that among cells, CD4+ most responsive, proportion JN.1-reactive cells strain SARS-CoV-2-unexposed Despite booster, reactivity BA.2.86. Conclusions: XBB.1.5-containing induced elderly. from BNT16b2-vaccinated, recognized RBD strains while showing JN.1. These results emphasize need for tailored strategies emerging vulnerable populations.

Язык: Английский

Interdisciplinary symposium on challenges and opportunities for vaccines: A comprehensive approach of current and future vaccine strategies to improve vaccine effectiveness in complex chronic infectious contexts DOI Creative Commons

Alex S. Siebner,

Marrium Habib,

Vanesa Osmani

и другие.

Vaccine X, Год журнала: 2025, Номер unknown, С. 100615 - 100615

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Emerging variants of Mpox virus and Tecovirimat resistance: Genomic Insights and Implications for Treatment Strategies. DOI
Santenna Chenchula, Shubham Atal,

Mohan Krishna Ghanta

и другие.

Virology, Год журнала: 2025, Номер 608, С. 110532 - 110532

Опубликована: Апрель 12, 2025

Язык: Английский

Процитировано

0
Current German Recommendations and International Research on the Use of COVID-19 Boosters among Health Care Providers in 2024: A Narrative Review DOI Creative Commons
Poramate Pitak‐Arnnop, Popchai Ngamskulrungroj, Nithi Mahanonda

и другие.

Medicina, Год журнала: 2024, Номер 60(3), С. 385 - 385

Опубликована: Фев. 25, 2024

While the World Health Organization (WHO) has de-escalated coronavirus disease 2019 (COVID-19) from a global health emergency, ongoing discussions persist as new viral variants. This article aimed to consolidate German recommendations and international research offer care providers (HCPs) comprehensive guide on COVID-19 boosters in 2024. The review outlines key Robert Koch Institute. HCPs should receive at least 12 months after their last vaccination or infection, contingent prevalent variant(s) region. However, excessive doses and/or frequent boosters, especially with mRNA vaccines, may lead immune imprinting, T-cell exhaustion, immunoglobulin (Ig) switching. Notably, this highlights significance of Ig, particularly IgA IgG subclasses, influencing infection risk progression. Furthermore, it explores implications vaccine technology potential adverse effects related dosing. In conclusion, provides analysis for HCPs, synthesising current recommendations, scientific debates, considerations optimising protection against SARS-CoV-2 evolving landscape post-pandemic era.

Язык: Английский

Процитировано

2
Global domination of the recently VoI-classified 'JN.1′ outcompeting other variants – Comparing the vaccines’ efficacy DOI Creative Commons
Ranjan K. Mohapatra,

Venkataramana Kandi,

Abhay Gaidhane

и другие.

Clinical Infection in Practice, Год журнала: 2024, Номер 22, С. 100358 - 100358

Опубликована: Апрель 1, 2024

Язык: Английский

Процитировано

2
Antigen-specific T helper cells and cytokine profiles predict intensity and longevity of cellular and humoral responses to SARS-CoV-2 booster vaccination DOI Creative Commons
Lukas Page, Kevin M. Dennehy,

Katharina Mueller

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Авг. 29, 2024

Introduction Pre-existent pools of coronavirus-specific or cross-reactive T cells were shown to shape the development cellular and humoral immune responses after primary mRNA vaccination against SARS-CoV-2. However, determinants booster remain incompletely understood. Therefore, we phenotypically functionally characterized spike antigen-specific helper (Th) in healthy, immunocompetent individuals correlated results with BNT162b2 over a six-month period. Methods Blood 30 healthy healthcare workers was collected before, 1, 3, 6 months their 3rd vaccination. Whole blood stimulated peptides analyzed using flow cytometry, 13-plex cytokine assay, nCounter-based transcriptomics. Results Spike-specific IgG levels at 1 month pre-existing CD154+CD69+IFN-γ+CD4+ effector memory as well spike-induced IL-2 IL-17A secretion. Early post-booster (1-month) (r=0.49), IL‑2 (r=0.58), IFN‑γ release (r=0.43) moderately respective long-term (6-month) responses. Sustained robust significantly associated S-specific (CD69+±CD154+±IFN-γ+) Th-cell frequencies before (p=0.038), especially double/triple-positive type-1 Th cells. Furthermore, levels, release, increased & IL‑4, IP‑10 MCP1, post-booster, respectively. On transcriptional level, induction pathways both T-cell proliferation antigen presentation indicative sustained spike-specific production post-booster. Using support vector machine models, pre-booster early predicted F1 scores 0.80-1.00. Discussion In summary, T-cellular signatures present adaptive Functional assays might facilitate identification potential non-responders.

Язык: Английский

Процитировано

2
In vitro antibody-mediated SARS-CoV-2 infection suppression through human ACE2 receptor blockade DOI

Priscilla S. Redd,

Alyssa D. Merting, John D. Klement

и другие.

Immunology Letters, Год журнала: 2024, Номер 268, С. 106887 - 106887

Опубликована: Июнь 24, 2024

Язык: Английский

Процитировано

0
T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects DOI Creative Commons
Irene Segato, Dalila Mele, Greta Forlani

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1451 - 1451

Опубликована: Дек. 23, 2024

Background/Objectives: New SARS-CoV-2 variants are continuously emerging, making it essential to assess the efficacy of vaccine-induced immune protection. Limited information is available regarding T cell responses BA.2.86 and JN.1 variants, particularly in elderly individuals. Methods: We evaluated total IgG against receptor-binding domain (RBD) ancestral strain, as well omicron subvariants, two groups subjects. One group consisted SARS-CoV-2-exposed individuals who were fully vaccinated with BNT162B2 mRNA vaccine, a booster dose updated 2023–2024 COVID-19 vaccine (XBB.1.5) at least 15 days after receiving vaccine. The second healthcare workers unexposed one month first-generation BNT162b2 activation-induced markers (AIM) IFN-γ secretion by flow cytometry ELISpot assays, respectively. Results: Elderly subjects showed reduced levels compared strain. stimulation resulted lower versus COVID-19-naïve group. AIM analysis that among cells, CD4+ most responsive, proportion JN.1-reactive cells strain SARS-CoV-2-unexposed Despite booster, reactivity BA.2.86. Conclusions: XBB.1.5-containing induced elderly. from BNT16b2-vaccinated, recognized RBD strains while showing JN.1. These results emphasize need for tailored strategies emerging vulnerable populations.

Язык: Английский

Процитировано

0